Benefit to Targeting Btk in Selected Patients With AML?

A preclinical study of ibrutinib provides compelling evidence that myeloid leukemias with mutatedG-CSFR have abnormal activation of Btk.

Source: CancerNetwork - July 24, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news